Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 9/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12855079 | 0.91 | BACE1 (0.36) | BACE1BACE2KCNN4BRAFF10 | |
| SCHEMBL969477 | 0.89 | BACE1 (0.39) | BACE1BACE2BRAF | |
| SCHEMBL933994 | 0.88 | BACE1 (0.35) | BACE1BACE2RORCKCNN4BRAF | |
| SCHEMBL934033 | 0.88 | BACE1 (0.35) | BACE1BACE2RORCKCNN4BRAF | |
| SCHEMBL934034 | 0.88 | BACE1 (0.35) | BACE1BACE2RORCKCNN4BRAF | |
| SCHEMBL933997 | 0.88 | BACE1 (0.35) | BACE1BACE2RORCKCNN4BRAF | |
| SCHEMBL18192862 | 0.88 | BACE1 (0.40) | BACE1BACE2HRH2TRPC5CACNA1H | |
| SCHEMBL18192806 | 0.88 | BACE1 (0.40) | BACE1BACE2HRH2TRPC5CACNA1H | |
| SCHEMBL13177595 | 0.81 | BACE1 (0.49) | BACE1BACE2CTSD | |
| SCHEMBL8035988 | 0.81 | BACE1 (0.49) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885RORC 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.